However, although inhibitors of PKM2 such as Shikonin and its analogs have recently been described and shown to inhibit cancer cell glycolysis (59), it is not clear that these compounds are suitable as therapeutic agents for targeting PKM2, because they also interact with PKM1 and other proteins (60). This evidence concerns the gene PKM and cancer.